Immuneering plummets following phase 2 data of atebimetinib for pancreatic cancer
Source: SeekingAlpha
2026-01-07 16:59:39 ET
More on Immuneering
- Immuneering: Clinical Catalyst In January, Cash Raised For Phase 3
- Immuneering Corporation 2025 Q3 - Results - Earnings Call Presentation
- Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript
- Immuneering to be added to the Nasdaq Biotechnology Index
- Immuneering GAAP EPS of -$0.38
Read the full article on Seeking Alpha
For further details see:
Immuneering plummets following phase 2 data of atebimetinib for pancreatic cancer
Verastem Inc.
NASDAQ: VSTM
VSTM Trading
-2.34% G/L:
$6.27 Last:
375,559 Volume:
$6.36 Open:
VSTM Latest News
VSTM Stock Data
$424,027,638
66,108,246
1.4%
15
N/A
Biotechnology & Life Sciences
Healthcare
US
Needham
